LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

LLY

740.33

+2.22%↑

JNJ

149.28

+0.65%↑

UNH

275.4

+3.05%↑

ABBV

180.67

+2.24%↑

NVO

63.6

-2.53%↓

Search

Danaher Corp

Cerrado

SectorSanidad

191.97 5.83

Resumen

Variación precio

24h

Actual

Mínimo

183.04

Máximo

191.15

Métricas clave

By Trading Economics

Ingresos

-132M

954M

Ventas

-797M

5.7B

P/B

Media del Sector

38.921

56.602

BPA

1.88

Rentabilidad por dividendo

0.66

Margen de beneficios

16.617

Empleados

61,000

EBITDA

367M

1.8B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+26.32% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.66%

2.45%

Próximas Ganancias

22 jul 2025

Fecha Próximo Dividendo

25 jul 2025

Próxima Fecha de Ex Dividendo

27 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-4.4B

144B

Apertura anterior

186.14

Cierre anterior

191.97

Noticias sobre sentimiento de mercado

By Acuity

31%

69%

88 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Danaher Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 abr 2025, 10:34 UTC

Ganancias

Danaher 1Q Results Decline But Top Estimates

5 feb 2025, 12:54 UTC

Ganancias

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 ene 2025, 11:44 UTC

Ganancias

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 oct 2024, 10:35 UTC

Ganancias

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

22 abr 2025, 10:02 UTC

Ganancias

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 abr 2025, 10:02 UTC

Ganancias

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 abr 2025, 10:02 UTC

Ganancias

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 abr 2025, 10:01 UTC

Ganancias

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 abr 2025, 10:01 UTC

Ganancias

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 abr 2025, 10:00 UTC

Ganancias

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22 abr 2025, 10:00 UTC

Ganancias

Danaher 1Q Adj EPS $1.88 >DHR

22 abr 2025, 10:00 UTC

Ganancias

Danaher 1Q EPS $1.32 >DHR

22 abr 2025, 10:00 UTC

Ganancias

Danaher 1Q Sales $5.74B >DHR

22 abr 2025, 10:00 UTC

Ganancias

Danaher 1Q Net $954M >DHR

29 ene 2025, 15:25 UTC

Charlas de Mercado
Ganancias

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 ene 2025, 13:56 UTC

Principales Noticias
Ganancias

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 ene 2025, 11:08 UTC

Ganancias

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 ene 2025, 11:07 UTC

Ganancias

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 ene 2025, 11:07 UTC

Ganancias

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 ene 2025, 11:02 UTC

Ganancias

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 ene 2025, 11:01 UTC

Ganancias

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 ene 2025, 11:01 UTC

Ganancias

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 ene 2025, 11:00 UTC

Ganancias

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 ene 2025, 11:00 UTC

Ganancias

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 ene 2025, 11:00 UTC

Ganancias

Danaher 4Q Net $1.09B >DHR

29 ene 2025, 11:00 UTC

Ganancias

Danaher 4Q EPS $1.49 >DHR

29 ene 2025, 11:00 UTC

Ganancias

Danaher 4Q Adj EPS $2.14 >DHR

29 ene 2025, 11:00 UTC

Ganancias

Danaher 4Q Sales $6.5B >DHR

22 oct 2024, 10:02 UTC

Ganancias

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 oct 2024, 10:02 UTC

Ganancias

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Comparación entre iguales

Cambio de precio

Danaher Corp previsión

Precio Objetivo

By TipRanks

26.32% repunte

Estimación a 12 Meses

Media 241.2 USD  26.32%

Máximo 265 USD

Mínimo 210 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Danaher Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

16 ratings

14

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

189.8851 / 196.5Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

88 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.